Stocks - r/Stocks Daily Discussion Wednesday - Apr 17, 2019 |
- r/Stocks Daily Discussion Wednesday - Apr 17, 2019
- Reuters - Apple accused in U.S. lawsuit of securities fraud over iPhone sales in China
- How to play 5G?
- Amazon to close domestic marketplace business in China - sources
- QCOM Vs. AAPL settlement. How I lost the opportunity to make $50,000 on a very stupid decision
- Chinese economic optimism lights global risk-on fire, sending global markets higher this morning
- Corbus Pharmeceuticals
- XELA E*Trade $9 Valuation
- Want to short Turkish markets, the best instrument?
- NEO
- Discussion on selling Apple amongst discussable factors
- Why is INTC way up pre-market?
- Perspective from older investors
- How can I short Medical/Medical Insurance Stocks?
- TTMI - >10% over 50 day SMA, just broke two resistance lines, already high volume
- Intel says it's exiting the 5G smartphone market, hours after Apple-Qualcomm settlement
- NASH DD
- Thoughts on Modern Times Group (MTG-B)?
- Hello everyone. Do you feel that we’re due for a recession similar to hat of 08-09 and 00-02?
- PFF ishares preferred ETF
- Insys ($INSY) and McKesson ($MCK) eviscerate by John Oliver
- Asian stocks
- Atvi advice
- Nervous to start. Any advice
| r/Stocks Daily Discussion Wednesday - Apr 17, 2019 Posted: 17 Apr 2019 01:06 AM PDT These daily discussions run from Monday to Friday including during our themed posts. Some helpful links:
If you have a basic question, for example "what is EPS," then google "investopedia EPS" and click the investopedia article on it; do this for everything until you have a more in depth question or just want to share what you learned. Please discuss your portfolios in the Rate My Portfolio sticky.. See our past daily discussions here. Also links for: Technicals Tuesday, Options Trading Thursday, and Fundamentals Friday. [link] [comments]  |
| Reuters - Apple accused in U.S. lawsuit of securities fraud over iPhone sales in China Posted: 17 Apr 2019 09:42 AM PDT Apple accused in U.S. lawsuit of securities fraud over iPhone sales in China (Reuters) - Apple Inc was accused in a new lawsuit of securities fraud for concealing a slump in demand for iPhones, particularly in China, leading to a $74 billion one-day slide in its market value once the truth became known. The complaint filed on Tuesday seeks damages for investors who bought Apple stock in the two months before Chief Executive Tim Cook on Jan. 2 unexpectedly reduced Apple's quarterly revenue forecast as much as $9 billion, in part because of the intensifying U.S. trade war with China. This is going to leave a mark. Cook shot the pooch with this deal. From then on Apple is now being seen as moving over to the darkside. 60% of revs derived from phone unit sales yet in his infinite wisdom Cook decides to eliminate phone sales unit metrics from future ER releases. CNBC protection racket won't help this time. [link] [comments]  |
| Posted: 17 Apr 2019 11:38 AM PDT We all know 5G is going to revolutionize the way we interact with technology in our world. This industry is in its infancy, but the stage is being set at this very moment. I have been looking into it for a while, but I'm having trouble finding an abundance of reliable resources on who is doing what in the market. What do you think the future looks like when 5G matures in 2025? And who do you think it puts on top? [link] [comments]  |
| Amazon to close domestic marketplace business in China - sources Posted: 17 Apr 2019 11:57 AM PDT SAN FRANCISCO/SHANGHAI (Reuters) - Amazon.com Inc plans to close its domestic marketplace business in China by mid-July, people familiar with the matter told Reuters on Wednesday, focusing efforts on its more lucrative businesses selling overseas goods and cloud services in the world's most populous country. [link] [comments]  |
| QCOM Vs. AAPL settlement. How I lost the opportunity to make $50,000 on a very stupid decision Posted: 16 Apr 2019 03:59 PM PDT Hello Everyone, I just needed a place to vent, because I just made the most stupid decision in my life, and I can't really justify it to myself or anyone that I know. Back in February, I decided that QCOMs case vs AAPL was putting a lot of pressure on the QCOMs stock price and realized that the options are very cheap considering the opportunity for a favorable outcome. I bought 75 April 18 call options with a strike price of 65 for $0.10 each, and till yesterday night I was still holding them. I live in Australia, so I am mostly sleeping during US trading hours. Yesterday, however, I woke up at 4 am and decided to put a limit sell order of $0.06 on my options to salvage my losses given that only 2 days are remaining till expiry, and went back to sleep. I wake up at 7 am to go to work, and see the news and realize that my options would have been worth a small fortune and the contract is being traded at $6 each which would have realized a 6000% return for me in 2 months. Long story short, I lost the opportunity to make $50,000 just because I made a very stupid decision when I woke up at 4 AM! I feel so disgusted with myself and I dont know what to do to feel better. I got everything right but screwed up at the last minute. I feel so angry with myself and having a mental breakdown, and I needed to let someone know what happened. How do I live myself and go on with my life after that? [link] [comments]  |
| Chinese economic optimism lights global risk-on fire, sending global markets higher this morning Posted: 17 Apr 2019 04:48 AM PDT US Stocks Preview Ahead of the Open
Stocks Trending in the News
International Stock Markets Recap
[link] [comments]  |
| Posted: 17 Apr 2019 09:44 AM PDT I recently stumbled across Corbus Pharmeceuticals and am extremely tempted to buy. Its currently hovering around $6.92 and has a price target of around $28. Zacks recently downgraded it from a buy to a hold, but analysts predict that the next year or two could be huge for growth. I was wondering if anyone had any insight. [link] [comments]  |
| Posted: 17 Apr 2019 10:13 AM PDT Does anyone have any input on this? Thanks to u/JoeysWorldTourMRE [link] [comments]  |
| Want to short Turkish markets, the best instrument? Posted: 17 Apr 2019 12:38 PM PDT I currently have exposure to Turkish assets (via some real estate that I can't liquidate). I would like to limit my downside in a potential crisis in a year or two, and I have never shorted a stock or bought any options. I was wondering if anyone out there can chime in with regards to the best instruments to take advantage of the downside risks (e.g. specific TUR ETF put options, or shorting) for the Turkish market? I understand some options are costly, and I was wondering if anyone identified the best (in terms of cost and time horizon) instruments to do so with the Turkish market. [link] [comments]  |
| Posted: 17 Apr 2019 08:14 AM PDT Hello, new investor looking to invest in the US based ETF HMUS tomorrow. It's traded on the NEO, and being new, have no idea how to access this market (being in Wisconsin). Can someone tell me what brokerage I might use to invest there? [link] [comments]  |
| Discussion on selling Apple amongst discussable factors Posted: 17 Apr 2019 01:19 PM PDT I personally believe Apple will struggle in the short term and I would like to hear more sense. They are entering markets that already competitive (video streaming, game streaming, credit card) I do not think these services will make up for the lacking iphone sales (another reason to sell, they are going to release poor iphone sales this april most likely). I dont think apple can compete with microsoft on streaming games, they already have a massive pool of customers with there product (xbox one). Disneys streaming service competing with netflix and prime video and thats alot of competition alone Apple may not get much of this portion either. Also they were just accused of fraudulent acts in china by masking there slumping sales. Then again this is speculation, please feel free to add your sense. I sold this stock today for a 16% gain (works for me lol), may buy back again later on when they dip I am with them for long term, they may struggle in the short term. [link] [comments]  |
| Why is INTC way up pre-market? Posted: 17 Apr 2019 05:35 AM PDT I would have thought with the new INTC is bailing from 5G it would be down. Not up. What am I missing? Right now INTC is up over 4%. [link] [comments]  |
| Perspective from older investors Posted: 17 Apr 2019 10:47 AM PDT I discovered free trading and I started building a portfolio. I am completely new. I read a lot, and held positions through December lows. My returns today hit 11% all time. During the last three months I'm up 11.61% vs 11% for the S&P 500 during the same time period. Is this rate of return typical? Is .61% a negligible market beat? [link] [comments]  |
| How can I short Medical/Medical Insurance Stocks? Posted: 17 Apr 2019 01:37 PM PDT Other than broad market etf shorts like QID are there any way's for me to short the Medical / Medical insurance industry. Like a reverse XLV? [link] [comments]  |
| TTMI - >10% over 50 day SMA, just broke two resistance lines, already high volume Posted: 17 Apr 2019 12:24 PM PDT I feel like I'm taking crazy pills. No one is talking about this stock anywhere, but all indicators tell me that this will keep rising and a good chance at really shooting up. Also, has $18.40 target price and 1.80 recommend score. [link] [comments]  |
| Intel says it's exiting the 5G smartphone market, hours after Apple-Qualcomm settlement Posted: 16 Apr 2019 05:03 PM PDT https://www.cnbc.com/2019/04/16/intel-announces-plans-to-pull-out-of-5g-smartphone-market.html Intel said on Tuesday it's pulling out of the 5G smartphone market and will provide further details later this month. Qualcomm dominates the market and earlier in the day announced a multi-year deal with Apple. [link] [comments]  |
| Posted: 17 Apr 2019 10:56 AM PDT Nonalcoholic Steatohepatitis NASH Market OverviewNonalcoholic steatohepatitis (NASH) is a liver disease caused by inflammation and damage brought on by the buildup of fat on the liver. A member of the nonalcoholic fatty liver diseases, NASH often causes no symptoms in those it affects and usually creates no problems. In some cases however, the buildup of fat around the liver leads to inflammation and tissue damage to the vital organ, preventing normal function. NASH can progress in patients, developing into fibrosis, cirrhosis or severe scarring of the liver which is often seen at the terminal stages of chronic liver disease. GlobalData forecasts that the NASH market will grow at a Compound Annual Growth Rate (CAGR) of 63% across the United States, United Kingdom, Japan, Germany, France, Italy, and Spain, reaching $18.3B by 2026. Amazingly, there are no current therapeutic options approved for the treatment of NASH. With the market open for the taking, many companies are partaking in the race to be the first to approval, over 55 companies to be exact. Currently, the largest segment of the NASH treatment options will derive from those benefiting patients with cirrhosis, with these treatments expected to account for over 60% of the NASH market by the 2026 mark and total sales of over $11.3B. In the 7 previously mentioned countries, the number of cases of NASH each year are expected to reach nearly 50 million by 2027, with the United States having about 50% prevalence, followed by Japan. As competition intensifies and pricing pressure from governments and society eroding sales of medicines for diabetes, rheumatoid arthritis and other previously profitable disease categories, with an over crowded field for developmental oncology therapeutics, the market and forecasters see NASH as an enormous new market for future profit that will accelerate a wave of deal making. Companies such as Pfizer are taking a look at new opportunities to continue their success and prevent diminishing returns in oversaturated markets. Disease Overview and Development The development of the disease is often argued among healthcare professionals, often both linked to factors such as obesity as well as genetic and epi-genetic predispositions. NASH has been observed to occur frequently alongside cardiovascular disease while NASH also increases coronary deposits creating a greater risk of cardiovascular events. Liver failure as the result of liver fibrosis and cirrhosis is a major result of the disease frequently creates the need of liver transplants. Liver disease in patients with NASH is the third leading cause of death in the patient population, while the leading cause of death is hepatocellular carcinoma, a lethal form of cancer. When deciphering when NAFLD becomes NASH, there is a score system in place dubbed the NAS score which was proposed for untreated patients based on histological analysis of liver biopsy and judged upon steatosis, lobular inflammation, and ballooning or cell degeneration. If a patient receives at least one count in each of the three categories or scores a 3 out of 8 total, the patient is considered NASH positive. One consequence of NASH is the development of liver fibrosis which is measured by a fibrosis score that goes from F0 (no fibrosis) to F4 (cirrhosis). The levels range from Type 1 being NAFL with steatosis alone, Type 2 being NAFL with steatosis plus inflammation, Type 3 being NASH with steatosis plus hepatocyte injury or ballooning, and Type 4 being NASH with steatosis plus fibrosis. After Type 4, the liver develops full cirrhosis. In the end, experts don't know why some people with a buildup of fat in the liver get NASH and some don't. It could be that something in the environment triggers the inflammation in those people. Or maybe it runs in their families. As mentioned above, there are a multitude of things that put people at risk for NASH and for liver damage including: Obesity. *Insulin resistance and type 2 diabetes. *High cholesterol and high triglycerides. *Metabolic syndrome. *Genetic and Epi-genetic disposition The continual increase of obesity in the western world and occurrence of type 2 diabetes along with high fat diets is going to continue to drive NASH. As the aging population from a fast food generation starts to mature in to their elderly years, the patient population for this disease is going to be startling. A majority of the patient population of NASH are 40 to 50 years old and have one or more of the problems listed above. Yet NASH can happen in people who have none of these risk factors and show no symptoms. A majority of patients report feeling fine and having never known of the disease manifestation. Common symptoms that appear as NASH progresses include fatigue, weight loss, general weakness, and aches around the liver and stomach. It is often years into the disease when NASH becomes severe that individuals begin to notice the symptoms and it is often too late. Off-Label (Supportive Therapies) Drugs for NASH Treatment Considering the market outlook, the number of treatment options for NASH is likely to increase significantly with the amount of research being poured into the disease, while the supportive therapies or off-label market share will begin to decrease from its recent peak of 100% in 2016 to 11% in 2027. Unmet Need Now, there is no approved therapy for the NASH treatment, causing several companies to divert their focus towards the development of targeted drugs with novel mechanism of action in the treatment of this disease. Patients with NASH are associated with a 50% higher chance of death than those patients diagnosed with just NAFLD, according to a recent study. Competition in NASH With the recent failure from Gilead, whose NASH drug trial STELLAR-4 did not achieve its primary endpoints, the race for FDA approval continues with tightening competition and leaders. I believe that first to market with this product will be crucial to success in the field over the next 2-3 years. While other drug candidates may see approval, a majority of patients will likely be dosing the first to market product to treat their debilitating disease. As over 50 different companies are moving to find the best treatment, there are several standouts who appear to be potential winners for both patients and investors. Here I am going to cover 4 different companies drug candidates handling NASH and a quick synopsis of their market position in timing and financials. From the early looks of things, we seem to have a winner. Intercept Pharmaceuticals Recently, Intercept Pharmaceuticals announced additional positive data from their REGENERATE Phase III study, which just so happens to be the very first successful Phase III study completed on patients with liver fibrosis due to NASH. With intentions to file for regulatory approval in not only the United States, but Europe as well in the second half of 2019, the recent dip in share price appears to be a tempting opportunity. Intercept focused on the study of obeticholic acid (OCA) in patients with liver fibrosis due to NASH. Once daily OCA dosed at 25 mg met primary endpoint in improving fibrosis of the liver with no worsening in NASH diagnosis through an 18-month analysis. It is important to note however, that there were two separate arms in the NASH study, with only one of the two meeting the endpoint. Based on a previously established agreement with the FDA, only one of the two endpoints was needed to conclude a successful trial. The primary efficacy analysis assessed efficacy at 18 months in 931 patients with stage 2 or 3 liver fibrosis due to NASH. There were fairly low levels of study discontinuation throughout the population which was nearly identical across both arms and placebo in the study: 16% in placebo, 17% in OCA 10 mg and 15% in OCA 25 mg. An additional pre-specified full efficacy analysis at 18 months added an exploratory cohort of 287 NASH patients with stage 1 liver fibrosis and additional risk factors who were at increased risk of progression to cirrhosis (N=1,218). Safety of the drug trial was done across 1,968 randomized patients who received a minimum of one dose of OCA or placebo. Adverse events were generally mild to moderate in severity and the most common were consistent with the known profile of OCA. The frequency of serious adverse events was similar across treatment arms: 11% in placebo, 11% in OCA 10 mg and 14% in OCA 25 mg. Unfortunately, there were 3 deaths in the study, yet none were considered related to treatment or the trial. The most common adverse event reported was dose-related pruritus: 19% in placebo, 28% in OCA 10 mg and 51% in OCA 25 mg. OCA treatment was found to be associated with an increase in LDL cholesterol, with a peak increase of 22.6 mg/dL at 4 weeks and subsequently reversing and approaching baseline at month 18, which happened to be consistent with previous trials and data with on OCA. Triglycerides rapidly and continually decreased in the OCA treatment arms through month 18. There was an associated risk of higher incidence of gallstones or cholecystitis in OCA 25 mg patients compared to 10 mg and placebo patients. More recently, Intercept announced that they provided additional positive data to backup their already successful Phase III study. Roughly three times as many patients in the OCA 25 mg group achieved an improvement of fibrosis by ≥2 stages compared to placebo (13.3% vs 4.5%; p=0.0008). In fibrosis by ≥1 stage, approximately three times as many patients in the OCA 25 mg group improved versus worsened at 38.0% vs 13.1%, while in contrast the placebo group saw 23.2% vs 20.9% respectively. Substantially more patients in the OCA 25 mg group achieved improvements in the key underlying features of NASH, including hepatocellular ballooning, lobular inflammation and normalization of alanine aminotransferase at baseline achieved compared to those in the placebo group. The company ended 2018 with a strong cash position of roughly $436.2 million and saw revenues of $177.8 million from Ocaliva, which is expected to reach approximately $240 million this year. The company does have a rather high burn rate however, producing a loss of $309.2 million throughout the year, which is actually a nearly 20% improvement on the loss the previous year. I expect that towards the end of 2019 and into 2018 Intercept will look to do a raise to help marketing their flagship NASH product as well as expand on their distribution channels of Ocaliva. With the NASH study coming to an end, the expenses are just transferring. Like I said, in the NASH space, first to market will be key. Intercept is clearly on their way. There are a few hurdles left in place, but the recent drop in price signals a buy to me. Will only one endpoint be the cause of no approval despite agreement by the FDA? Madrigal Pharmaceuticals What can I say, I love Madrigal Pharmaceuticals. You can review my synopsis and run down of the company through my post history. While I won't use this portion to rehash what I have already written about the company, I will be expanding on their initiation of their Phase III study on multinational, double-blind, randomized, placebo-controlled MGL-3196 in patients with NASH and fibrosis to resolve NASH and reduce progression of cirrhosis. The study will utilize biopsy confirmed NASH with stage 2 or 3 fibrosis and receive a placebo, 80 mg, or 100 mg dose of resmetirom. A second liver biopsy will be taken at the end of 1 year from first dose in the first 900 patients treated to determine if the endpoint of whether resmetirom shows a significant difference in hepatocyte ballooning, lobular inflammation, and no worsening of the fibrosis stage. The company will also be focusing on reducing in LDL-cholesterol and improvement in fibrosis stage by 1-point or more at the 52-week mark. The study will continue for a total of 54 months. Looking at Phase II of the study, the CEO of Madrigal was quoted, "In Phase 2, 25% of all resmetirom treated patients, and 37% of treated patients who were on adequate doses of resmetirom, achieved the Phase 3 NASH resolution endpoint (NASH resolution with at least a 2-point reduction in NAS and no fibrosis stage worsening); both results demonstrated statistically significant differences relative to placebo." One key difference in Phase III is the increased dosing of patients. It is hoped that the higher doses might prove more effective than those in Phase II, as the higher dose in the concluded phase did show higher efficacy. As you might know, MGL-3196 has been proven to be quite the contender for treating NASH, showing efficacy and tolerability through a majority of patients. I have been in this company for many months now, and am very confident in them. I am concerned however with Intercept Pharmaceuticals getting approval within the year, while Madrigal Pharmaceuticals still has many months before their Phase III study is concluded. I will say, Madrigal is my favorite and pick. This current price level, far off its recent highs, is more than attractive to entice me to continue buying. Viking Therapeutics Viking therapeutics has been the hot topic of conversation when NASH is involved among many retail traders and investors. I believe that this is mainly due to the low entry point, people believe that it is poised to rocket the same way that Madrigal had upon positive data. Whether this is the actual case, I am not sure. I do know however that the stock tends to run off great news, showing signs of high volatility. Let's take a look. Viking Therapeutics' novel drug VK2809 is a selective thyroid hormone receptor beta agonist which has a high selectivity for liver tissue which suggests treatment for metabolic disorders such as NASH. The company presented an in vivo model in mice of glycogen storage disease at a conference last October showing that VK2809 led to overall improvement in liver health by restoration of autophagy, reduction in steatosis, reduction of inflammation and liver size. All of these positive outcomes pointed to the conclusion that VK2809 is a potential candidate for the treatment of NAFLD and NASH. Further, the company presented results from their Phase II study of VK2809 in patients with NAFLD and elevated LDL-cholesterol at the 12-week point, demonstrating achievement of both primary and secondary endpoints. The primary endpoint was the statistically significant reduction of LDL-cholesterol compared to a placebo. The company demonstrated this reduction of LDL-C at both every day and every other day dosing. The company's secondary endpoints of reducing liver fat content at 12 weeks of treatment was extremely successful, with over 90% of patients demonstrating a greater than 30% reduction in liver fat content in just 3 months. The company just provided an update on their Phase II data, demonstrating that 100% of patients receiving 5 mg of VK2809 dosed daily were experiencing more than 30% reduction from baseline in liver fat content at week 12. Now THAT is statistically significant. I think one of the biggest notes to make about this company is the $302 million in cash as of the end of 2018 that the company has will allow them to operate through 2021 at a minimum. This is an uninterrupted 2 years of cash runway. No fear of dilution or offerings in the near future, which for a smaller market cap company like Viking Therapeutics, is massive. Phase IIb of the study is set to initiate in the second half of 2019, making this year a key year for Viking. The company only needs to continue Phase II to completion and obtain liver biopsies of their patients. Having patients with no confirmed NASH through biopsies is a hurting point for the company. I believe once they make that step and continue positive results, they can easily see similar gains as Madrigal had. However hopeful I am for Viking, I remain realistic. I am debating on adding some to my portfolio in the near future when news starts to die and the price begins to pullback as I know this is a high volatility stock. The downsides listed above are coupled with the fact that this company is still likely 6+ years away from approval. Definitely a downer. Other Notable Contenders (listed favorite first): *GENFIT's Elafibranor *Allergan's Cenicriviroc *Galectin's Belapectin [link] [comments]  |
| Thoughts on Modern Times Group (MTG-B)? Posted: 17 Apr 2019 10:53 AM PDT MTG & NENT Group have just split into two separate companies. I'd like some opinions on what people thing of MTG now after the split? [link] [comments]  |
| Hello everyone. Do you feel that we’re due for a recession similar to hat of 08-09 and 00-02? Posted: 17 Apr 2019 09:59 AM PDT I create this post because unlike back in the days, we all have plenty of information available. Also, a lot of FUD around a recession crawling up on us has been all over the news for the past year or so; which makes me think, are we really going to head into a recession? I don't think so. At least not until the fud comes down and everyone is bullish again. "Whenever you find yourself on the side of the majority, it is time to pause and reflect." - Mark Twain [link] [comments]  |
| Posted: 17 Apr 2019 09:25 AM PDT Can someone explain the benefits of owning this? At first I was intrigued because it was a qualified dividend but then i realized all the ETFs are qualified dividends. So PFF offers a a yield and low volatile income but it's price appreciation is extremely minimal. What is the hook for people who buy these? I was considering buying 100 shares of this or instead just adding the my current etf holdings. [link] [comments]  |
| Insys ($INSY) and McKesson ($MCK) eviscerate by John Oliver Posted: 17 Apr 2019 09:14 AM PDT Opioids Criss II: Last Week Tonight with John Oliver (HBO). Video of the segment has almost 4 million views. [link] [comments]  |
| Posted: 17 Apr 2019 08:37 AM PDT I would like to get exposure to Asia/Pacific region in my dividend portfolio. Do any of you have some interesting stocks that I can do some research on? [link] [comments]  |
| Posted: 17 Apr 2019 08:23 AM PDT I bought a large position in atvi in 2014 for ~20 cost basis. Sold half at $83. Still have 10% of my portfolio here, I would like it to be 2.5%. When deciding to sell I ask myself would I buy at the current price or not. At 44 I think I would buy. Despite recent performance and stagnant growth I think the future ~ 5+ years could be good. But I'm overweight in atvi and if they dont turn around I'm gonna be butthurt I didn't take my gains. How would you guys go about reducing this overweight position? (I know this is a tough complicated decision that is ultimately going to be based on your expectations of future events) [link] [comments]  |
| Posted: 17 Apr 2019 07:40 AM PDT Hey guys id really like to start investing but unfamiliar with stocks. Any advice? How much to start with? Even just want to fully buy a couple of stocks to get ny feet wet. [link] [comments]  |
| You are subscribed to email updates from Stocks - Investing and trading for all. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment